Cere­nion Signs €2.28 mil­lion dis­tri­b­u­tion agree­ment with INNO­VACAREMD in Italy

Cere­nion has signed a €2.28 mil­lion dis­tri­b­u­tion agree­ment with Ital­ian med­ical tech­nol­o­gy com­pa­ny INNO­VACAREMD, mark­ing a sig­nif­i­cant mile­stone in the company’s Euro­pean expan­sion strat­e­gy.

With the agree­ment, INNO­VACAREMD will become the exclu­sive dis­trib­u­tor of Cerenion’s C‑Trend EEG Sta­tion in Italy. The part­ner­ship estab­lish­es a ded­i­cat­ed com­mer­cial chan­nel in one of Europe’s largest health­care mar­kets and is expect­ed to accel­er­ate the adop­tion of con­tin­u­ous EEG mon­i­tor­ing solu­tions in Ital­ian hos­pi­tals.

INNO­VACAREMD, found­ed in 2020, is led by Mar­co Scor­sato, who brings more than 30 years of expe­ri­ence in med­ical devices and in vit­ro diag­nos­tics, togeth­er with Fed­eri­co Scor­sato, who con­tributes strong IT exper­tise and oper­a­tional exe­cu­tion. The com­pa­ny has estab­lished nation­wide cov­er­age in Italy, with a focus on advanced res­pi­ra­to­ry and neu­ro­log­i­cal tech­nolo­gies and com­pre­hen­sive cus­tomer sup­port.

The col­lab­o­ra­tion is already pro­gress­ing, with ini­tial hos­pi­tal engage­ments and prod­uct demon­stra­tions com­plet­ed to sup­port ear­ly adop­tion. Based on cur­rent mar­ket activ­i­ty, INNO­VACAREMD is tar­get­ing sev­er­al mil­lion euros in C‑Trend EEG Sta­tion sales over the next two years.

“This agree­ment rep­re­sents an piv­otal step in our com­mer­cial growth in Europe,” said Kiki Di Napoli, Vice Pres­i­dent of Sales at Cere­nion. “INNO­VACAREMD brings strong mar­ket knowl­edge and exe­cu­tion capa­bil­i­ty, pro­vid­ing a sol­id foun­da­tion to scale our pres­ence in Italy and expand access to con­tin­u­ous EEG mon­i­tor­ing.”

Mar­co Scor­sato, CEO of INNO­VACAREMD, com­ment­ed: “We are pleased to part­ner with Cere­nion to intro­duce advanced EEG mon­i­tor­ing solu­tions to the Ital­ian mar­ket. We see clear demand for tech­nolo­gies that sup­port more effi­cient neu­ro­log­i­cal assess­ment and improved clin­i­cal deci­sion-mak­ing.”

The agree­ment sup­ports Cerenion’s strat­e­gy to expand inter­na­tion­al­ly through tar­get­ed dis­tri­b­u­tion part­ner­ships and to con­vert grow­ing clin­i­cal inter­est into scal­able rev­enue across key Euro­pean mar­kets.

Source: Cere­nion